|
Sunday,
6 November 2005, Pre-Meeting Short Courses |
SUNDAY
MORNING COURSES 8:00-12:00:
Use of Pharmacoeconomic / Economic / Outcomes Research Information (AM) 8:00-12:00
Elements of Pharmaceutical Pricing
Faculty:
Jack Mycka,
President, Optimar Strategic Consulting LLC, Montclair,
NJ, USA; Renato Dellamano PhD, President, ValueVector
(Value Added Business Strategies), Milan, ItalyCourse Description:
This course is designed to cover the elements of
pharmaceutical pricing decisions. It will cover the
issues, information and processes employed and the role of
pharmacoeconomics in helping to shape pricing decisions.
This course will be interactive and is designed for
those with some experience in either pharmacoeconomics or
pharmaceutical pricing.
Pharmacoeconomics / Economic Methods (AM)
8:00-12:00
Transferability of Cost-Effectiveness Data between
Countries
Faculty:
Michael Drummond PhD, Director, University of York,
Centre for Health Economics, York, UK;
Andrea Manca PhD, MSc, Wellcome Trust Fellow in
Health Services Research, Centre for Health Economics,
University of York, York, UK; Marco Barbieri MSc,
Associate Lecturer and Research Associate, University
Pompeu Fabra and Innovus Research (UK) Ltd, Barcelona,
Spain; Samuel Aballea MS, Research Analyst, Innovus
Research (UK) Ltd, High Wycombe, UKCourse Description:
Although the number of countries requiring an economic
dossier as part of the submission dossier for public
reimbursement of new drugs is growing, the pharmaceutical
industry cannot conduct economic evaluations in every
potential market. Clinical trials are increasingly done in
international settings in order to quickly recruit a
sufficient number of patients and to have at least some
economic data from multiple countries. However, national
decision makers require country-specific or
region-specific data on health care costs and are only
willing to accept foreign data or international data when
they are translated to their own specific setting. But
guidelines on how to do this do not exist. This course
starts with a discussion of factors that make economic
data more difficult to transfer from one country to other
countries than clinical data. Then we will review the
methods that have been presented to offer a solution to
this problem and their pros and cons. These methods
include various types of regression-based methods and
Markov models. This course is for those with basic
understanding of cost calculation and modeling.
Use of Pharmacoeconomic / Economic / Outcomes Research Information (AM) 8:00-12:00
Health Care and Reimbursement Systems in Europe
Faculty:
Gordon Carey MS, MBA, Cambridge Pharma Consultancy Ltd., Cambridge, UK;
Chris Francis BSc, Analyst, Cambridge Pharma
Consultancy, Cambridge, Cambridgeshire, UK
Course Description:
This course will describe
and compare various European health care systems, and
will include information on health care financing and
resource allocation mechanisms. Various issues
encountered when defining benefit packages or
introducing new health care technology will be
discussed. The course will also cover newer developments
in European health care system organization and
management, such as provision and purchaser-provider
splits. This includes a discussion of the current role
of health technology assessment and health economic
analysis for reimbursement decisions in Europe.
Participants will have the possibility to apply the
taught course contents in a country-specific case study.
This course is designed for those with little
experience with health care systems and reimbursement in
Europe.
Modeling (AM)
8:00-12:00
Bayesian
Methods in Economic Evaluations
Faculty:
Anthony O'Hagan PhD, Professor of Statistics, University
of Sheffield, Sheffield, South Yorkshire, UK;
Jeremy E.
Oakley PhD, Lecturer, Department of Probability and
Statistics, University of Sheffield, Sheffield, UK;
John
Williams Stevens BSc, Statistician, AstraZeneca,
Leicestershire, UK
Course Description: This course is designed to provide an
overview of the Bayesian approach and its application to
health economics and outcomes research. The course will
cover basic elements of Bayesian statistics, discuss
differences between Bayesian and classical (frequentist)
approaches, and demonstrate how to apply the Bayesian
approach to clinical trials and cost-effectiveness
analyses. Available software will be discussed, and
examples of studies will be presented. This course is for
those with a basic appreciation of statistics and
probability.
Discrete
Event Simulation for Economic Analyses
Faculty: J.Jaime Caro MDCM, FCRPC, FACP, Adjunct Professor
of Medicine, Adjunct Professor of Epidemiology and
Biostatistics, McGill University, Montreal PQ and
Scientific Director, Caro Research Institute, Concord, MA,
USA;
Jörgen Möller MSc, Mech Eng, Simulation Specialist,
Caro Research Institute, Concord, MA, USA
Course Description: This course will provide a basic
understanding of the key concepts of discrete event
simulation. The focus will be on the use of these
simulation models to address pharmacoeconomic (and
device-related) problems. The course will be structured
around practical exercises. Topics to be covered are: Why
DES? Dynamic simulation as a tool; Components of a DES;
How do you build a model? Modeling of processes and
resource use; modeling of variables and decisions. It will
address the ISPOR Task Force Reports on Good Research
Practices – Modeling Studies / Cost-Effective Analysis
alongside Clinical Trials. If time
permits, simple animation will be demonstrated. We will
use ARENA to build simple models. Participants who wish to
have hands-on experience should bring their laptops.
Instructors will distribute training versions of Arena.
After the course the participants should understand how to
interpret the results of a DES and have an understanding
of simulation as a tool - how, where and when to use it.
The participants should also be able to map simple dynamic
processes in ARENA and build simple models.
Quality of Life / Patient-Reported Outcomes /
Preference-based Methods (AM) 8:00-12:00
Utility Measurements (Preference-Based Techniques)
Faculty: Jan Busschbach PhD, Senior Investigator,
Department for Medical Psychology and Psychotherapy and
Erasmus Medical Center, Rotterdam, The Netherlands; Elly
Stolk MSc, Institute for Medical Technology Assessment (iMTA),
Erasmus University Medical Center Rotterdam, The
Netherlands.
Course Description:
Utility measurement is a method of
determining an individual's preference for a certain
outcome represented by a quantitative score (utility).
During this course, methods for measuring preference-based
outcomes like the standard gamble, time trade-off, and
visual analogue scale will be demonstrated. Utility
measurement however is not only about mastering these
techniques; it is about using them in such a way that
health care decision makers can apply the results, for
instance in QALY-analyses. For this purpose, one needs to
be aware of shortcomings of the available utility measures
and potential solutions. Furthermore one should be aware
of the decision-making context and the way results are
interpreted. To equip participants with expertise in the
field of utility measurement, the most important issues
will be discussed: for instance we will consider potential
insensitivity of generic instruments for particular
disease specific problems, and discuss to what extent
adaptation of generic or disease-specific quality of life
instruments may offer a solution. This will be
demonstrated with an exercise. Also the issue of "whose
values count: patient values or values from the general
public?" will be discussed. Finally we turn to the
interpretation in the context of resource allocation. This
course is for those with some experience with
quality-of-life measures in health economic evaluation.
8th Annual European Congress Main Page |
